Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease

IF 6.7 1区医学 Q1 CHEMISTRY, MEDICINAL

Phytomedicine Pub Date : 2025-05-21 DOI:10.1016/j.phymed.2025.156889

Tom Ryu , Beom Sun Chung , Jaejun Lee , Ji Won Han , Hyun Yang , Keungmo Yang

{"title":"Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease","authors":"Tom Ryu , Beom Sun Chung , Jaejun Lee , Ji Won Han , Hyun Yang , Keungmo Yang","doi":"10.1016/j.phymed.2025.156889","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern linked to increased risks of cardiovascular disease, chronic kidney disease (CKD), and premature mortality. Ginkgo biloba has shown potential therapeutic benefits in conditions characterized by metabolic dysfunction. This study aimed to evaluate the potential protective effects of Ginkgo biloba supplementation on overall survival (OS) and the incidence of cardiovascular and renal outcomes specifically in MASLD patients.</div></div><div><h3>Methods</h3><div>This cohort study included 402,476 participants from the UK Biobank, categorized into MASLD and No steatotic liver disease (SLD) cohorts. Ginkgo biloba users and non-users were compared using inverse probability of treatment weighting to balance baseline characteristics. Clinical outcomes were assessed using Cox proportional hazards models, with subgroup analyses.</div></div><div><h3>Results</h3><div>Ginkgo biloba supplementation was associated with significantly improved OS [hazard ratio (HR) = 0.79, 95 % confidence interval (CI): 0.64–0.98, <em>p</em> = 0.034) and reduced risks of cardiovascular events (HR = 0.82, 95 % CI: 0.66–1.00, <em>p</em> = 0.012) and CKD (HR = 0.73, 95 % CI: 0.56–0.96, <em>p</em> = 0.012) in the MASLD cohort, while no significant benefits were observed in the No SLD cohort. Subgroup analyses indicated enhanced benefits in older adults, males, individuals with BMI ≥ 25 kg/m², and diabetic patients. The beneficial effects were pronounced in patients with advanced fibrosis.</div></div><div><h3>Conclusion</h3><div>Ginkgo biloba supplementation is associated with improved survival and reduced cardiovascular and renal risks in MASLD patients, particularly in high-risk subgroups. These findings highlight the potential of Ginkgo biloba as an adjunctive therapy in MASLD management. This is the first large-scale study to examine the potential impact of Ginkgo biloba supplementation on clinical outcomes in MASLD, with fibrosis-stratified analyses providing insights into its differential effects across disease severity.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"143 ","pages":"Article 156889"},"PeriodicalIF":6.7000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytomedicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0944711325005276","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern linked to increased risks of cardiovascular disease, chronic kidney disease (CKD), and premature mortality. Ginkgo biloba has shown potential therapeutic benefits in conditions characterized by metabolic dysfunction. This study aimed to evaluate the potential protective effects of Ginkgo biloba supplementation on overall survival (OS) and the incidence of cardiovascular and renal outcomes specifically in MASLD patients.

Methods

This cohort study included 402,476 participants from the UK Biobank, categorized into MASLD and No steatotic liver disease (SLD) cohorts. Ginkgo biloba users and non-users were compared using inverse probability of treatment weighting to balance baseline characteristics. Clinical outcomes were assessed using Cox proportional hazards models, with subgroup analyses.

Results

Ginkgo biloba supplementation was associated with significantly improved OS [hazard ratio (HR) = 0.79, 95 % confidence interval (CI): 0.64–0.98, p = 0.034) and reduced risks of cardiovascular events (HR = 0.82, 95 % CI: 0.66–1.00, p = 0.012) and CKD (HR = 0.73, 95 % CI: 0.56–0.96, p = 0.012) in the MASLD cohort, while no significant benefits were observed in the No SLD cohort. Subgroup analyses indicated enhanced benefits in older adults, males, individuals with BMI ≥ 25 kg/m², and diabetic patients. The beneficial effects were pronounced in patients with advanced fibrosis.

Conclusion

Ginkgo biloba supplementation is associated with improved survival and reduced cardiovascular and renal risks in MASLD patients, particularly in high-risk subgroups. These findings highlight the potential of Ginkgo biloba as an adjunctive therapy in MASLD management. This is the first large-scale study to examine the potential impact of Ginkgo biloba supplementation on clinical outcomes in MASLD, with fibrosis-stratified analyses providing insights into its differential effects across disease severity.

查看原文本刊更多论文

补充银杏叶对代谢功能障碍相关脂肪变性肝病临床结果的保护作用

代谢功能障碍相关的脂肪变性肝病（MASLD）是一个日益增长的全球健康问题，与心血管疾病、慢性肾脏疾病（CKD）和过早死亡的风险增加有关。银杏已显示出潜在的治疗作用，以代谢功能障碍为特征的条件。本研究旨在评估补充银杏叶对MASLD患者总生存期（OS）以及心血管和肾脏结局发生率的潜在保护作用。方法本队列研究纳入来自英国生物银行的402,476名参与者，分为MASLD和非脂肪变性肝病（SLD）队列。银杏使用者和非使用者使用治疗加权逆概率来平衡基线特征进行比较。采用Cox比例风险模型评估临床结果，并进行亚组分析。结果补充银杏叶显著改善了MASLD组的OS(风险比（HR) = 0.79, 95%可信区间（CI）： 0.64-0.98, p = 0.034），降低了心血管事件（HR = 0.82, 95% CI: 0.66-1.00, p = 0.012）和CKD （HR = 0.73, 95% CI: 0.56-0.96, p = 0.012）的风险，而在no SLD组中没有观察到显著的益处。亚组分析显示，老年人、男性、BMI≥25 kg/m²的个体和糖尿病患者获益更大。在晚期纤维化患者中有明显的有益效果。结论补充银杏叶可提高MASLD患者的生存率，降低心血管和肾脏风险，特别是在高危亚组中。这些发现突出了银杏叶作为MASLD治疗辅助疗法的潜力。这是第一次大规模研究银杏叶补充剂对MASLD临床结果的潜在影响，纤维化分层分析提供了不同疾病严重程度的差异效应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytomedicine 医学-药学

CiteScore

10.30

自引率

5.10%

发文量

670

审稿时长

91 days

期刊介绍： Phytomedicine is a therapy-oriented journal that publishes innovative studies on the efficacy, safety, quality, and mechanisms of action of specified plant extracts, phytopharmaceuticals, and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of herbal medicinal products, preparations, and purified compounds with defined and consistent quality, ensuring reproducible pharmacological activity. Founded in 1994, Phytomedicine aims to focus and stimulate research in this field and establish internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy, and safety of phytomedicines.